Literature DB >> 8006318

A meta-analysis of the effect of oral and inhaled corticosteroids on growth.

D B Allen1, M Mullen, B Mullen.   

Abstract

This analysis summarizes studies comparing attained heights with expected heights of children with asthma treated with inhaled or oral corticosteroids. The possible moderating effects of treatment duration, and dosage and asthma severity are also examined. A preliminary database of 95 articles rendered 21 includable studies representing 810 patients with asthma, which yielded 29 tests of the corticosteroid-growth effect. Statistical integration of the results of these studies revealed a significant but small tendency for corticosteroid therapy in general to be associated with diminished final height (Z = 2.328, p = 0.01, mean r = -0.023). However, this effect varied for the specific drugs under consideration. As expected, significant weak growth impairment was observed for prednisone (Z = 2.137, p = 0.0164, mean r = -0.295) and "other oral corticosteroids" (Z = 9.107, p = 2.44E-18, mean r = -0.260). On the other hand, a significant moderate tendency was observed for inhaled beclomethansone dipropionate therapy to be associated with attaining normal stature (Z = 7.395, p = 2.17E-13, mean r = +0.432). There was no statistical evidence for beclomethasone dipropionate therapy to be associated with growth impairment at higher doses, for longer therapy durations, or among patients with more severe asthma. This meta-analytic integration indicates that available studies of inhaled beclomethasone dipropionate therapy do not show an association between its use and the adverse effect of diminished stature.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8006318     DOI: 10.1016/s0091-6749(94)70043-5

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  33 in total

1.  Childhood asthma.

Authors:  A Morris; C Mellis
Journal:  West J Med       Date:  2001-11

2.  The impact of corticosteroids on growth and bone health.

Authors:  T Mushtaq; S F Ahmed
Journal:  Arch Dis Child       Date:  2002-08       Impact factor: 3.791

Review 3.  Inhaled corticosteroids in childhood asthma: long-term effects on growth and adrenocortical function.

Authors:  Alessandro Salvatoni; Elena Piantanida; Luana Nosetti; Luigi Nespoli
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 4.  Management of asthma in adults: current therapy and future directions.

Authors:  R H Green; C E Brightling; I D Pavord; A J Wardlaw
Journal:  Postgrad Med J       Date:  2003-05       Impact factor: 2.401

5.  Inhaled corticosteroids and the risk of diabetes among the elderly.

Authors:  Nandini Dendukuri; Lucie Blais; Jacques LeLorier
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

Review 6.  Asthma and other recurrent wheezing disorders in children (chronic).

Authors:  Stephen William Turner; Amanda Jane Friend; Augusta Okpapi
Journal:  BMJ Clin Evid       Date:  2012-01-18

7.  EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

Authors:  J N Hoes; J W G Jacobs; M Boers; D Boumpas; F Buttgereit; N Caeyers; E H Choy; M Cutolo; J A P Da Silva; G Esselens; L Guillevin; I Hafstrom; J R Kirwan; J Rovensky; A Russell; K G Saag; B Svensson; R Westhovens; H Zeidler; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-07-27       Impact factor: 19.103

8.  Reference values for bone mineral density according to age with body size adjustment in Korean children and adolescents.

Authors:  Kyung Hee Yi; Jin Soon Hwang; Eun Young Kim; Jun Ah Lee; Dong Ho Kim; Jung Sub Lim
Journal:  J Bone Miner Metab       Date:  2013-07-06       Impact factor: 2.626

Review 9.  Fortnightly review: modern drug treatment of chronic asthma.

Authors:  B J Lipworth
Journal:  BMJ       Date:  1999-02-06

Review 10.  Treatment of childhood asthma: how do the available options compare?

Authors:  David Coghlan; Colin Powell
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.